Pharmacological Treatment of Sexually Offending Behavior in People With Mental Retardation/Developmental Disabilities
Donald L. Sherak, M.D.

The limited literature from the 1970's to the present that specifically addresses the pharmacologic treatment of sexually offending behavior in people with mental retardation/developmental disabilities (MR/DD) is reviewed within the larger context of the pharmacologic treatment of sexual offending behaviors. The significance of comorbid conditions, both in the assessment and treatment of MR/DD individuals and also in the assessment and treatment of sexual offending behaviors is reviewed. The problem of sexual offending behaviors is also considered within the larger context of the behavioral difficulties and unique vulnerabilities of the MR/DD populations. Several illustrative clinical cases are discussed. The efficacy and potential side effects associated with the use of hormonal agents medroxyprogesterone and cyproterone acetate in the treatment of sexual offending behaviors is reviewed. The theoretical basis for the use of selective serotonin reuptake agents is discussed as well as a review of clinical trials and case reports of the use of these agents. The problems and possible benefits from the appropriate use of antipsychotic agents is also briefly reviewed